Compare Open Text Corporation (OTEX) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Open Text Corporation vs Recursion Pharmaceuticals Inc — how do they compare? Open Text Corporation trades at $23.25 (market cap $5.62B), while Recursion Pharmaceuticals Inc trades at $3.98 (market cap $2.31B). The key difference: Open Text Corporation is far larger — about 2.4× Recursion Pharmaceuticals Inc's market cap, and Open Text Corporation pays a 4.84% dividend while Recursion Pharmaceuticals Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Open Text Corporation for 23 Days and Recursion Pharmaceuticals Inc for 22 Days on average.
| OTEX | RXRX | |
|---|---|---|
Market Cap | $5.62B | $2.31B |
Volume | 1,217,244 | 40,478,768 |
Sector | Technology | Health |
52-Week High | $39.69 | $6.79 |
52-Week Low | $20.01 | $2.84 |
Typical Hold Time | 23 Days | 22 Days |
Enterprise Value | $10.64B | $1.83B |
Dividend Yield | 4.84% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
OpenText (OTEX) trades at $23.14, up 1.89% with a bullish technical signal despite mixed moving averages. The company shows strong fundamentals with a P/E of 8.97 and consistent earnings beats, including Q2 2026 EPS of $1.23 beating expectations by 20.6%. Recent debt refinancing activities and a strategic AI partnership with Cohere highlight management's focus on growth and financial flexibility.
OTEX presents a compelling value opportunity with discounted valuation multiples and improving cloud momentum, though elevated debt levels and competitive pressures remain key risks. Analyst consensus targets $28.30 (22% upside) with 42% buy ratings, suggesting cautious optimism for the software company's transformation efforts.
RXRX trades at $4.27, down 7.78% today, with a bullish technical signal from moving averages but negative profitability. The company reported a net loss of -$644.76M in 2025, with revenue of $74.26M, and has beaten earnings estimates in two of the last three quarters. Recent news highlights strategic AI partnerships and pipeline expansion, though financial performance remains challenged.
The outlook is mixed: analyst consensus is 40% buy, 60% hold, with no sell ratings, indicating cautious optimism for long-term AI-driven growth. Key risks include persistent cash burn, high valuation multiples, and slow revenue growth. Upside depends on successful drug development and partnership milestones, but near-term profitability remains elusive.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Open Text Corporation
Open Text Corporation is a global leader in Enterprise Information Management (EIM) software and solutions. The company provides a comprehensive platform that helps organizations manage, secure, and leverage their unstructured digital content, including documents, emails, and media files. OTEX's offerings span content management, business process management, customer experience management, and security, serving large enterprises across various industries worldwide.
Read more on OTEX →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
